CD79B and diffuse large B-cell lymphoma: In a phase I/II trial in patients with relapsed or refractory DLBCL, ibrutinib monotherapy produced an objective clinical response (OCR) of varying degree and duration in 37% of ABC-DLBCL cases, with higher response rates, reaching approximately 80%, in tumors with concurrent CD79B and MYD88L265P mutations [44].